Cyclic GMP in Vascular Relaxation | Zendy

Christian Krawutschke | Zendy; Doris Koesling | Zendy; Michael Russwurm | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cyclic GMP in Vascular Relaxation

Author(s) -

Christian Krawutschke,

Doris Koesling,

Michael Russwurm

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306133

Subject(s) - phosphodiesterase 3 , pde10a , vascular smooth muscle , nitric oxide , phosphodiesterase , cgmp dependent protein kinase , intracellular , second messenger system , cgmp specific phosphodiesterase type 5 , natriuretic peptide , chemistry , atrial natriuretic peptide , zaprinast , biophysics , medicine , microbiology and biotechnology , biochemistry , endocrinology , biology , enzyme , protein kinase a , smooth muscle , heart failure , erectile dysfunction , cyclin dependent kinase 2

In the vascular system, cyclic GMP (cGMP) in smooth muscle cells plays an important role for blood vessel relaxation. Intracellular concentrations of cGMP are thought to be determined by the action of cGMP-generating guanylyl cyclases (sensitive to nitric oxide or natriuretic peptides) and cGMP-degrading phosphodiesterases (PDE1, PDE3, and PDE5). Because functionally relevant cGMP elevations are not accessible to conventional methods, we applied real-time imaging with a fluorescence resonance energy transfer (FRET)-based cGMP indicator to follow nitric oxide- and natriuretic peptide-induced cGMP signals in living smooth muscle cells and analyzed the contribution of the miscellaneous cGMP-generating and cGMP-degrading enzymes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research